Introduction

Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. It accounts for approximately 10% of all hematologic cancers and remains incurable for most patients, though treatment advances have improved survival. Early detection is critical because the disease often progresses silently, with patients presenting at advanced stages when bone destruction, renal impairment, anemia, and recurrent infections have already set in. Imaging plays a pivotal role not only in diagnosis but also in staging, risk stratification, and monitoring treatment response. Over the past decade, significant refinements in imaging technology have shifted the paradigm from late-stage detection of bone lesions to early identification of marrow involvement and extramedullary disease. This article reviews traditional imaging methods, explores the latest advances in imaging techniques for early detection of multiple myeloma, and discusses their impact on clinical outcomes and future directions.

Traditional Imaging Methods

Whole‑Body Skeletal Survey

The whole‑body skeletal survey (WBSS) has long been the standard for detecting myeloma‑related bone disease. It consists of a series of plain X‑rays of the axial and appendicular skeleton. While widely available and relatively inexpensive, WBSS has significant limitations. It can only detect osteolytic lesions that have destroyed at least 30–50% of bone mineral density, meaning early‑stage lesions are often invisible. Furthermore, X‑rays cannot visualize bone marrow infiltration or soft‑tissue plasmacytomas. The sensitivity of WBSS for detecting focal lesions is low, estimated at 30–40% compared with advanced imaging. This shortcoming can delay diagnosis and lead to underestimation of disease burden.

Conventional Computed Tomography

Traditional whole‑body CT (WBCT) has better resolution than X‑rays and can detect smaller lytic lesions. However, it exposes patients to higher radiation doses and still cannot differentiate active disease from treated, quiescent lesions. Moreover, CT does not provide functional or metabolic information, limiting its ability to identify extramedullary disease or early marrow involvement. Because of these drawbacks, conventional CT has largely been superseded by low‑dose CT protocols and hybrid imaging, as discussed below.

Advances in Imaging Technologies

Recent technological progress has introduced more sensitive and specific imaging modalities that can detect myeloma‑related changes long before bone destruction occurs. The most impactful advances include magnetic resonance imaging (MRI), positron emission tomography combined with computed tomography (PET/CT), and whole‑body low‑dose CT (WBLDCT).

Whole‑Body Low‑Dose CT

WBLDCT represents a major improvement over conventional X‑ray survey. It uses significantly less radiation than standard WBCT while providing high‑resolution images of the entire skeleton. WBLDCT is particularly effective at identifying small lytic lesions in areas difficult to evaluate on X‑rays, such as the ribs, spine, and pelvis. Studies have shown that WBLDCT detects bone disease in 40–60% more patients than WBSS, often upstaging patients from smoldering to active myeloma. The International Myeloma Working Group now recommends WBLDCT as the initial imaging modality for suspected myeloma when advanced imaging is available. Its role in early detection is especially valuable for smoldering myeloma and MGUS patients who are at risk of progression.

Magnetic Resonance Imaging

MRI is the most sensitive imaging modality for detecting bone marrow infiltration before cortical bone destruction occurs. With whole‑body MRI (WBMRI) using fast sequences and diffusion‑weighted imaging (DWI), radiologists can identify focal lesions, diffuse marrow involvement, and extramedullary disease with high precision. DWI provides information about cellular density and water diffusion, which correlates with tumor cellularity and can distinguish active from treated disease. Clinical evidence indicates that WBMRI detects abnormalities in up to 50% of patients with suspected myeloma who have a negative skeletal survey. Furthermore, the presence of more than one focal lesion on MRI is a strong predictor of progression from smoldering to symptomatic myeloma. MRI is also essential for evaluating spinal cord compression and guiding biopsy.

PET/CT and PET/MRI

Positron emission tomography combined with CT or MRI integrates metabolic activity with anatomical detail. The most common radiotracer is ¹⁸F‑FDG, which is taken up by metabolically active myeloma cells. PET/CT can identify both medullary and extramedullary disease, assess disease activity, and detect minimal residual disease after therapy. Several large studies have demonstrated that FDG‑PET/CT has higher sensitivity and specificity than WBSS and conventional CT for detecting myeloma bone lesions, with pooled sensitivity around 85% and specificity over 90%. Its ability to identify residual metabolic activity after treatment is a strong predictor of progression‑free and overall survival. The emergence of PET/MRI combines the excellent soft‑tissue contrast of MRI with the functional data of PET, potentially reducing radiation exposure while providing comprehensive staging. Though PET/MRI is still less common, early studies indicate it may be superior to PET/CT for detecting diffuse marrow disease.

Other Emerging Modalities

Advances in contrast‑enhanced MRI using dynamic contrast‑enhanced (DCE) and arterial spin labeling (ASL) sequences offer quantitative measures of microvascular perfusion and permeability, which can be altered in myeloma‑infiltrated marrow. Whole‑body CT perfusion and sodium fluoride PET (¹⁸F‑NaF) are under investigation for detecting bone metabolism changes. Additionally, dual‑energy CT (DECT) can characterize marrow composition and improve detection of small lesions by exploiting material decomposition. While these techniques are not yet standard, they exemplify the trend toward more precise, functional imaging.

Comparative Effectiveness of Imaging Modalities

Sensitivity and Specificity

Head‑to‑head comparisons of the modern modalities have been performed in multiple prospective studies. A meta‑analysis of 29 studies found that WBMRI had the highest sensitivity (92%) for detecting focal lesions, followed by PET/CT (85%) and WBLDCT (75%). Specificity was highest for PET/CT (93%) because functional activity helps differentiate benign from malignant lesions. WBLDCT had excellent specificity (98%) for lytic bone disease but could not detect marrow involvement without cortical destruction. These differences underscore the complementary nature of these techniques: WBMRI excels at marrow infiltration, PET/CT at active disease and extramedullary sites, and WBLDCT at detecting early cortical lesions.

Impact on Staging and Risk Stratification

The revised International Staging System (R‑ISS) for multiple myeloma includes the number of focal lesions on MRI as an independent prognostic factor. Patients with more than one focal lesion on MRI have a significantly shorter time to progression and overall survival. Similarly, the number of PET‑avid lesions and the metabolic parameter SUVmax have been correlated with clinical outcomes. Integration of imaging findings with cytogenetic risk and serum biomarkers allows more accurate risk stratification. For instance, in smoldering myeloma, the presence of two or more focal lesions on MRI or PET/CT is considered an indication for treatment, even in the absence of CRAB criteria (hyperCalcemia, Renal failure, Anemia, Bone lesions). This earlier intervention paradigm relies heavily on modern imaging.

Guidelines and Recommendations

Major guidelines have evolved to reflect these advances. The International Myeloma Working Group (IMWG) now recommends that if advanced imaging (PET/CT, WBMRI, or WBLDCT) is available, it should replace skeletal survey for initial evaluation. The National Comprehensive Cancer Network (NCCN) recommends either WBLDCT or PET/CT as first‑line imaging at diagnosis. For follow‑up, PET/CT is preferred for assessing response and detecting relapse. MRI is the modality of choice when spinal cord compression or extramedullary disease is suspected. These recommendations are driven by the superior early detection capabilities of modern imaging.

Impact on Early Detection and Patient Outcomes

Transition to Earlier Intervention

The ability to detect minimal bone or marrow involvement has directly enabled earlier therapeutic interventions. Patients with smoldering myeloma who progress to active disease can be identified months to years before clinical symptoms appear, allowing initiation of chemotherapy, targeted agents, or immunotherapy at a point when the disease burden is low. Randomized trials have shown that early treatment in high‑risk smoldering myeloma improves survival, and imaging criteria are central to defining that risk. Moreover, modern imaging helps detect extramedullary disease, which is associated with a particularly poor prognosis and may require different treatment strategies.

Monitoring Treatment Response

Advanced imaging is not limited to diagnosis; it is critical for evaluating response to therapy. A significant proportion of patients who achieve complete hematologic remission (no detectable monoclonal protein in serum or urine) still have active disease on PET/CT or MRI. This minimal residual disease (MRD) status has powerful prognostic value. For example, in a landmark study, patients who were MRD‑negative by both flow cytometry and PET/CT after transplantation had a median progression‑free survival of 96 months versus 22 months for those who were MRD‑positive. PET‑directed assessment of metabolic response also helps tailor therapy, potentially avoiding ineffective treatments and reducing toxicity.

Quality of Life and Cost‑Effectiveness

Early detection reduces the incidence of skeletal‑related events such as pathologic fractures, spinal cord compression, and severe bone pain. By enabling less aggressive initial therapy and fewer hospitalizations, modern imaging can improve quality of life and reduce long‑term healthcare costs. A cost‑effectiveness analysis from the UK showed that replacing skeletal survey with WBLDCT for initial staging saved approximately £2,300 per patient due to earlier detection and avoidance of delayed diagnoses. As imaging technology becomes more affordable and accessible, similar benefits are expected globally.

Challenges and Considerations

Accessibility and Cost

Despite the clear advantages, advanced imaging is not universally available. Many centers in low‑ and middle‑income countries still rely on skeletal surveys. The high cost of PET/MRI and the limited number of trained radiologists for interpreting whole‑body MRI sequences pose barriers. Efforts to reduce costs through low‑dose protocols, abbreviated MRI, and artificial intelligence‑assisted interpretation are ongoing.

Radiation Exposure

While WBLDCT and PET/CT involve ionizing radiation, modern low‑dose techniques have reduced effective doses to levels comparable to screening mammography. Nevertheless, cumulative exposure from repeated scanning over a patient’s lifetime remains a concern, particularly in younger patients with long‑expected survival. This has motivated the shift toward MRI‑based or PET/MRI approaches that eliminate radiation entirely.

Interpretation Pitfalls

False positives can occur with any imaging modality. Benign bone lesions, hemangiomas, infections, and marrow reconversion can mimic myeloma involvement on MRI and CT. On PET/CT, inflammation or recent fracture may cause increased FDG uptake, leading to false positives. Standardized reporting criteria (e.g., the Myeloma Imaging Reporting and Data System – MY‑RADS) are being developed to improve consistency and reduce inter‑reader variability.

Need for Standardized Protocols

Variability in imaging protocols across institutions hinders comparability in clinical trials and routine care. Uniform acquisition parameters, lesion classification, and response criteria are essential for the accurate interpretation of studies. The IMWG has published consensus guidelines for the use of MRI, PET/CT, and WBLDCT, but adherence remains variable.

Future Directions

Artificial Intelligence and Radiomics

Machine learning and deep learning models are being trained to detect myeloma lesions on WBLDCT, MRI, and PET/CT with accuracy comparable or superior to expert radiologists. Radiomics—the extraction of high‑dimensional texture and shape features from imaging—can quantify lesion heterogeneity and predict biology, such as chromosomal abnormalities or drug resistance. These tools promise to enhance early detection further and automate the assessment of disease burden, reducing workload and improving reproducibility.

Molecular and Functional Imaging

Novel tracers beyond FDG are under investigation, such as ¹¹C‑methionine PET for amino acid metabolism, ⁶⁸Ga‑pentixafor for CXCR4 expression, and ⁸⁹Zr‑labeled antibodies targeting CD38 or BCMA. These probes can potentially detect myeloma cells with higher specificity and allow imaging of the bone marrow microenvironment. Combined with liquid biopsy (circulating tumor DNA and free light chains), molecular imaging could enable near‑real‑time monitoring of clonal evolution and minimal residual disease.

Integration with Liquid Biopsy

The combination of advanced imaging with circulating tumor cell enumeration and plasma cell‑free DNA analysis offers a comprehensive picture of disease activity. For example, a patient with a negative PET/CT but rising circulating tumor DNA levels may have occult disease not yet visible on scans. Prospective trials are evaluating the synergy of these modalities to guide treatment intensification or de‑escalation.

Personalized Surveillance Programs

As risk‑adapted strategies become more common, imaging frequency and modality may be tailored to each patient’s risk profile. Low‑risk smoldering myeloma patients might be monitored with annual WBMRI, while high‑risk patients could undergo PET/CT every 6 months with concurrent biomarker assessments. Such programs aim to maximize early detection while minimizing cost and patient burden.

Conclusion

Advances in imaging have fundamentally improved the early detection of multiple myeloma. Whole‑body low‑dose CT, MRI, and PET/CT now detect disease at stages where intervention can alter the natural history, reduce skeletal complications, and improve survival. The integration of functional and anatomical imaging provides a comprehensive assessment of disease burden and activity, guiding personalized treatment decisions. While challenges related to accessibility, cost, and standardization remain, ongoing developments in artificial intelligence, molecular imaging, and multi‑omics approaches promise even greater precision in the coming years. Clinicians involved in the care of patients with plasma cell dyscrasias must stay abreast of these evolving technologies to optimize outcomes and ensure that early detection translates into tangible patient benefits.

External links: